Trials / Terminated
TerminatedNCT02191566
S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy
A Phase II Study of Adjuvant Chemotherapy of S-1 With Oxaliplatin in Gastric Cancer at Stage IIIB/ IV (AJCC 6th) After D2 Resection
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Kangbuk Samsung Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
After curative resection, patients with stage IIIB-IV (M0) gastric cancer were given chemotherapy as follows: S-1 orally at 80 mg/m2 divided in two daily doses for 14 days and oxaliplatin at 130 mg/m2 intravenously over 2 h every 21 days as one cycle. S1 was administered for 16 cycles (12 months) and oxaliplatin for 8 cycles (6 months).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | S-1 (452500ACH) | S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months |
| DRUG | OXALIPLATIN (205803BIJ) | Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2019-10-01
- Completion
- 2019-10-01
- First posted
- 2014-07-16
- Last updated
- 2022-12-08
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02191566. Inclusion in this directory is not an endorsement.